Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan

- Conclusions Support Registration Strategy Including NASH Cirrhosis -
- Detailed Data to be Presented in Late-Breaker Poster at EASL Meeting -

SAN DIEGO, March 26, 2015 -- Conatus Pharmaceuticals Inc. (CNAT) today announced top-line results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically significant (p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing compared to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of approximately 39% in the emricasan treatment arm and approximately 14% in the placebo arm were similar to results observed in previous trials.

Published: 26 March 2015

Written by Editor

Nasdaq Up on News Project Update

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer

CALGARY, March 25, 2015 Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN^®, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

"This is the second jurisdiction where we have gained Orphan Designation for the use of REOLYSIN^® in the treatment of these gynecological cancers and our first grant in the European Union," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to secure Orphan Drug Designation for selected cancers as a way to support further development of REOLYSIN^® in key jurisdictions globally."

Published: 25 March 2015

Written by Editor

Nasdaq

Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results

-- On Track to Report Top-Line Phase II Data from Dex-IN Post Op Day 1 Trial in Mid 2015 --
-- Strengthened Company with Expected Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes --

MALVERN, Pa., March 25, 2015 -- Recro Pharma, Inc. (REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain, today reported financial results for the fourth quarter and full year ended December 31, 2014.

"In late 2014 and early 2015 we made significant advancements on both the clinical and corporate fronts," said Gerri Henwood, Recro Pharma's President and Chief Executive Officer. "Our Phase II Post Op Day 1 trial is progressing and we expect to receive results from our interim analysis shortly and top-line results in mid 2015.

Published: 25 March 2015

Written by Editor

Nasdaq Financial Results Up on News

VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)

-- Interim Data Demonstrate Statistically Significant Improvement in Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin(R)) --

TEL AVIV, Israel, March 25, 2015 -- VBL Therapeutics (VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). Study results will be presented in conjunction with the American Society of Cancer Oncology (ASCO) Annual Meeting, May 29th-June 2nd, 2015 in Chicago, Illinois.

Published: 25 March 2015

Written by Editor

Nasdaq Up on News Project Update

Immunovaccine Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma

Trial to Test Efficacy in Diffuse Large B cell Lymphoma Patients with Measurable Disease

HALIFAX, NOVA SCOTIA--(Marketwired - Mar 24, 2015) - Immunovaccine Inc. ("Immunovaccine" or "IMV") (IMV.TO), a clinical stage vaccine and immunotherapy company, today announced that it has treated the first patient with diffuse large B cell lymphoma (DLBCL) in a Phase 2 clinical study of its lead cancer immunotherapy DPX-Survivac. The Company-sponsored trial is evaluating DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. DPX-Survivac is designed to activate killer T cells of the immune system against the survivin antigen found in a wide variety of solid tumors and blood cancers.

Published: 24 March 2015

Written by Editor

TSX Project Update

Conatus Pharmaceuticals Inc ( CNAT )

Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan

Oncolytics Biotech Inc ( ONC / ONCY )

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer

Recro Pharma Inc ( REPH )

Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results

VBL Therapeutics (VBLT)

VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)

Immunovaccine Inc ( IMV )

Immunovaccine Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma